Literature DB >> 23529928

The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Natalia Rydz1, Laura L Swystun, Colleen Notley, Andrew D Paterson, J Jacob Riches, Kate Sponagle, Boonchai Boonyawat, Robert R Montgomery, Paula D James, David Lillicrap.   

Abstract

Genetic variation in or near the C-type lectin domain family 4 member M (CLEC4M) has been associated with plasma levels of von Willebrand factor (VWF) in healthy individuals. CLEC4M is a lectin receptor with a polymorphic extracellular neck region possessing a variable number of tandem repeats (VNTR). A total of 491 participants (318 patients with type 1 von Willebrand disease [VWD] and 173 unaffected family members) were genotyped for the CLEC4M VNTR polymorphism. Family-based association analysis on kindreds with type 1 VWD demonstrated an excess transmission of VNTR 6 to unaffected individuals (P = .0096) and an association of this allele with increased VWF:RCo (P = .029). CLEC4M-Fc bound to VWF. Immunofluorescence and enzyme-linked immunosorbent assay demonstrated that HEK 293 cells transfected with CLEC4M bound and internalized VWF. Cells expressing 4 or 9 copies of the CLEC4M neck region VNTR showed reduced interaction with VWF relative to CLEC4M with 7 VNTR (CLEC4M 4%-60% reduction, P < .001; CLEC4M 9%-45% reduction, P = .006). Mice expressing CLEC4M after hydrodynamic liver transfer have a 46% decrease in plasma levels of VWF (P = .0094). CLEC4M binds to and internalizes VWF, and polymorphisms in the CLEC4M gene contribute to variable plasma levels of VWF.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529928      PMCID: PMC3722568          DOI: 10.1182/blood-2012-10-457507

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Authors:  Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges Rivard; Dilys Rapson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

Review 2.  Clearance mechanisms of von Willebrand factor and factor VIII.

Authors:  P J Lenting; C J M VAN Schooten; C V Denis
Journal:  J Thromb Haemost       Date:  2007-04-07       Impact factor: 5.824

3.  Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels.

Authors:  Carina J M van Schooten; Cécile V Denis; Ton Lisman; Jeroen C J Eikenboom; Frank W Leebeek; Jenny Goudemand; Edith Fressinaud; H Marijke van den Berg; Philip G de Groot; Peter J Lenting
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

4.  Polymorphisms in the C-type lectin genes cluster in chromosome 19 and predisposition to severe acute respiratory syndrome coronavirus (SARS-CoV) infection.

Authors:  H Li; N L-S Tang; P K-S Chan; C-Y Wang; D S-C Hui; C Luk; R Kwok; W Huang; J J-Y Sung; Q-P Kong; Y-P Zhang
Journal:  J Med Genet       Date:  2008-08-12       Impact factor: 6.318

5.  N-linked glycosylation of VWF modulates its interaction with ADAMTS13.

Authors:  Thomas A J McKinnon; Alain C K Chion; Alexander J Millington; David A Lane; Mike A Laffan
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

6.  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Authors:  W L Nichols; M B Hultin; A H James; M J Manco-Johnson; R R Montgomery; T L Ortel; M E Rick; J E Sadler; M Weinstein; B P Yawn
Journal:  Haemophilia       Date:  2008-03       Impact factor: 4.287

7.  A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.

Authors:  Lisa Gallinaro; Maria Grazia Cattini; Maryta Sztukowska; Roberto Padrini; Francesca Sartorello; Elena Pontara; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan; Alessandra Casonato
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

8.  Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo.

Authors:  Carina J van Schooten; Shirin Shahbazi; Evelyn Groot; Beatrijs D Oortwijn; H Marijke van den Berg; Cécile V Denis; Peter J Lenting
Journal:  Blood       Date:  2008-06-16       Impact factor: 22.113

Review 9.  The C type lectins DC-SIGN and L-SIGN: receptors for viral glycoproteins.

Authors:  Pierre-Yves Lozach; Laura Burleigh; Isabelle Staropoli; Ali Amara
Journal:  Methods Mol Biol       Date:  2007

Review 10.  DC-SIGN and L-SIGN: the SIGNs for infection.

Authors:  Ui-Soon Khoo; Kelvin Y K Chan; Vera S F Chan; C L Steve Lin
Journal:  J Mol Med (Berl)       Date:  2008-05-06       Impact factor: 4.599

View more
  44 in total

1.  Von Willebrand factor is reversibly decreased during torpor in 13-lined ground squirrels.

Authors:  Scott Cooper; Shawn Sell; Luke Nelson; Jennifer Hawes; Jacob A Benrud; Bridget M Kohlnhofer; Bradley R Burmeister; Veronica H Flood
Journal:  J Comp Physiol B       Date:  2016-01       Impact factor: 2.200

2.  von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.

Authors:  Nicoletta Sorvillo; Robin B Hartholt; Esther Bloem; Magdalena Sedek; Anja ten Brinke; Carmen van der Zwaan; Floris P van Alphen; Alexander B Meijer; Jan Voorberg
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

3.  Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Authors:  Veronica H Flood; Pamela A Christopherson; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Daniel B Bellissimo; Rupa A Udani; Mahua Dasgupta; Raymond G Hoffmann; Margaret V Ragni; Amy D Shapiro; Jeanne M Lusher; Steven R Lentz; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Marilyn J Manco-Johnson; Ralph A Gruppo; Lisa N Boggio; Kate T Montgomery; Anne C Goodeve; Paula D James; David Lillicrap; Ian R Peake; Robert R Montgomery
Journal:  Blood       Date:  2016-02-09       Impact factor: 22.113

Review 4.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

5.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

6.  The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Authors:  Veronica H Flood; Jessica Garcia; Sandra L Haberichter
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

Review 7.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

8.  The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen.

Authors:  Laura L Swystun; Kenichi Ogiwara; Jesse D Lai; Juha R M Ojala; Orla Rawley; Fanny Lassalle; Colleen Notley; Olle Rengby; Alison Michels; Kate Nesbitt; Karl Tryggvason; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-06-20       Impact factor: 5.824

Review 9.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

Review 10.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.